Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer-Reference-Cited by-同舟云学术

Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer

Published:2019-08-19 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Narita Shintaro,Nomura Kyoko^ORCID,Hatakeyama Shingo^ORCID,Takahashi Masahiro,Sakurai Toshihiko,Kawamura Sadafumi^ORCID,Hoshi Senji,Ishida Masanori,Kawaguchi Toshiaki,Ishidoya Shigeto,Shimoda Jiro,Sato Hiromi,Mitsuzuka Koji,Tochigi Tatsuo,Tsuchiya Norihiko,Ohyama Chikara,Arai Yoichi,Nagashima Kengo^ORCID,Habuchi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-48600-8.pdf

Reference22 articles.

1. Tsao, C. K. & Oh, W. K. First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care? J Clin Oncol, JCO2017774315, https://doi.org/10.1200/jco.2017.77.4315 (2018).

2. Vale, C. L. et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet. Oncology 17, 243–256, https://doi.org/10.1016/s1470-2045(15)00489-1 (2016).

3. Fizazi, K. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377, 352–360, https://doi.org/10.1056/NEJMoa1704174 (2017).

4. Gravis, G. et al. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Eur Urol 68, 196–204, https://doi.org/10.1016/j.eururo.2014.09.022 (2015).

5. Glass, T. R., Tangen, C. M., Crawford, E. D. & Thompson, I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 169, 164–169, https://doi.org/10.1097/01.ju.0000042482.18153.30 (2003).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach;Cancers;2024-01-23

2. Diagnostic et définition des stades du cancer de la prostate métastatique hormonosensible;Urologie in der Praxis;2023-11-23

3. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis;Clinical Genitourinary Cancer;2023-09

4. Diagnosis and staging of metastatic hormone-sensitive prostate cancer;Die Urologie;2023-02-03

5. Novel quantitative software for automatically excluding red bone marrow on whole‐body magnetic resonance imaging in patients with metastatic prostate cancer: A pilot study;International Journal of Urology;2022-12-20